Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03585153Enrolling By Invitation

Multicenter Assessment of the Pancreas in Type 1 Diabetes

Role: collaborator

NCT04774224Phase 2Completed

Baricitinib in New-onset Type 1 Diabetes

Role: lead

NCT04848272Phase 1Active Not Recruiting

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Role: lead

All 3 trials loaded